Similar articles

• Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.

  Waeber C, Rigo M, Chinaglia G, Probst A, Palacios JM. Waeber C, et al. Synapse. 1991 Aug;8(4):270-80. doi: 10.1002/syn.890080405. Synapse. 1991. PMID: 1656540
• The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.

  Huot P, Lévesque M, Parent A. Huot P, et al. Brain. 2007 Jan;130(Pt 1):222-32. doi: 10.1093/brain/awl332. Epub 2006 Dec 2. Brain. 2007. PMID: 17142832
• Parkinson's disease, Huntington's disease and tardive dyskinesia. Neurochemical pathology and treatment.

  Tolosa ES. Tolosa ES. Minn Med. 1979 Feb;62(2):101-6. Minn Med. 1979. PMID: 155195 No abstract available.
• [Huntington chorea. Review of the most recent aspects of research].

  Albano C, Farinini D, Tassinari T, Caponnetto C, Bacigalupo F. Albano C, et al. Riv Neurol. 1985 Jul-Aug;55(4):247-55. Riv Neurol. 1985. PMID: 2997905 Review. Italian.
• The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).

  Marsden CD. Marsden CD. Mod Trends Neurol. 1975;6:141-66. Mod Trends Neurol. 1975. PMID: 127927 Review. No abstract available.